<SEC-DOCUMENT>0001157523-17-001937.txt : 20170713
<SEC-HEADER>0001157523-17-001937.hdr.sgml : 20170713
<ACCEPTANCE-DATETIME>20170712212352
ACCESSION NUMBER:		0001157523-17-001937
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170712
FILED AS OF DATE:		20170713
DATE AS OF CHANGE:		20170712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Aurinia Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001600620
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36421
		FILM NUMBER:		17962565

	BUSINESS ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
		BUSINESS PHONE:		250-708-4272

	MAIL ADDRESS:	
		STREET 1:		#1203-4464 MARKHAM STREET
		CITY:			VICTORIA BC
		STATE:			A1
		ZIP:			V8Z 7X8
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a51588345.htm
<DESCRIPTION>AURINIA PHARMACEUTICALS INC. 6-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <p style="text-align: center">
      <br>
      <font style="font-family: Times New Roman; font-size: 16pt"><b>UNITED
      STATES</b></font><b><font style="font-family: Times New Roman; font-size: 16pt"><br style="font-family: Times New Roman; font-size: 16pt"></font><font style="font-family: Times New Roman; font-size: 16pt">SECURITIES
      AND EXCHANGE COMMISSION</font></b><br><font style="font-family: Times New Roman; font-size: 10pt"><b>Washington,
      D.C. 20549</b></font>
    </p>
    <hr style="color: #000000; text-align: center; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 14pt"><b>FORM 6-K</b></font>
    </p>
    <hr style="color: #000000; text-align: center; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>&#160;</b></font><b><font style="font-family: Times New Roman; font-size: 12pt">REPORT
      OF FOREIGN PRIVATE ISSUER</font></b><br><font style="font-family: Times New Roman; font-size: 12pt"><b>PURSUANT
      TO RULE 13A-16 OR 15D-16 UNDER THE</b></font><br><font style="font-family: Times New Roman; font-size: 12pt"><b>SECURITIES
      EXCHANGE ACT OF 1934</b></font><br>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>Dated</b></font><font style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>July
      12, 2017</b></font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><b>Commission
      File Number</b></font><b> 001-36421</b>
    </p>
    <hr style="color: #000000; text-align: center; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <font style="font-size: 24pt"><b>AURINIA PHARMACEUTICALS INC.</b></font><br><b>(Exact
      name of Registrant as specified in its charter)</b><br>
    </p>
    <hr style="color: #000000; text-align: center; height: 1.0 pt; width: 100%">


    <p style="text-align: center">
      <b>N/A</b><br><b>(Translation of Registrant&#8217;s Name)</b><br><br>
    </p>
    <p style="text-align: center">
      <b>#1203-4464 Markham Street</b><br><b>Victoria, British Columbia</b><br><b>V8Z7X8</b><br><b>(250)
      708-4272</b><br><b>(Address and telephone number of registrant&#8217;s
      principal executive offices)</b>
    </p>
    <hr style="color: #000000; text-align: center; height: 1.0 pt; width: 100%">


    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether the registrant files or will file annual reports
      under cover of Form 20-F or Form 40-F.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Form 20-F &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><font style="font-family: Times New Roman; font-size: 10pt">
      &#160;&#160;&#160;&#160;Form 40-F&#160; </font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(1):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: left">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark if the registrant is submitting the Form 6-K in paper as
      permitted by Regulation S-T Rule 101(b)(7):&#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font><br>
    </p>
    <p style="text-indent: 30.0px; text-align: justify">
      <font style="font-family: Times New Roman; font-size: 10pt">Indicate by
      check mark whether by furnishing the information contained in this Form,
      the registrant is also thereby furnishing the information to the
      Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
      of 1934.</font>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt">Yes &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8864;</font><font style="font-size: 12pt">&#160;&#160;&#160;&#160;</font><font style="font-family: Times New Roman; font-size: 10pt">
      No &#160;</font><font style="font-family: Arial Unicode MS; font-size: 12pt">&#8414;</font>
    </p>
    <p style="font-size: 10pt; text-indent: 30.0px">
      This Form 6-K is hereby filed and incorporated by reference into the
      Registrant&#8217;s Registration Statement on Form F-10 (File No. 333-206994).
    </p>
    <p style="text-indent: 60.0px">

    </p>
    <div style="margin-right: 0pt; margin-bottom: 10pt; text-indent: 0pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 10pt"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-family: Times New Roman; font-size: 10pt"><b>SIGNATURES</b></font>
    </p>
    <p style="text-indent: 30.0px">
      <font style="font-family: Times New Roman; font-size: 10pt">Pursuant to
      the requirements of the Securities Exchange Act of 1934, the registrant
      has duly caused this report to be signed on its behalf by the
      undersigned, thereunto duly authorized.</font>
    </p>
    <p style="text-indent: 30.0px">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt">
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            July 12, 2017.
          </p>
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Aurinia Pharmaceuticals Inc.</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td colspan="3" valign="top" style="padding-left: 0.0px; text-align: center">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; padding-bottom: 2.0px; width: 4%; text-align: left">
          By:
        </td>
        <td colspan="2" valign="top" style="border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; text-align: left; border-bottom-style: solid">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 6%">

        </td>
        <td style="width: 44%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 4%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 7%; text-align: left">
          Name:
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 39%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Celia Economides
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 6%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 44%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 4%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 7%; text-align: left">
          Title:
        </td>
        <td valign="top" style="padding-left: 0.0px; width: 39%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Vice President, Public Affairs
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">

    </p>
    <div style="margin-right: 0pt; margin-bottom: 10pt; text-indent: 0pt; width: 100%; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="font-family: Times New Roman; font-size: 10pt; text-align: center">
          2
        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <b>EXHIBIT&#160;INDEX</b>
    </p>
    <p style="text-align: center">

    </p>
<div style="text-align:left">
    <table cellspacing="0" style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt">
      <tr>
        <td valign="bottom" style="border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 7%; text-align: left; border-bottom-style: solid">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Exhibit</b>
          </p>
        </td>
        <td valign="bottom" style="padding-left: 0.0px; padding-bottom: 2.0px; width: 5%; text-align: left">
          &#160;
        </td>
        <td valign="bottom" style="border-bottom-width: 1.0pt; padding-left: 0.0px; border-bottom-color: black; width: 88%; text-align: left; border-bottom-style: solid">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Description of Exhibit</b>
          </p>
        </td>
      </tr>
      <tr>
        <td style="width: 7%">

        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 88%; text-align: left">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="padding-left: 0.0px; width: 7%; text-align: left; white-space: nowrap; padding-right: 0.0px">
          99.1
        </td>
        <td style="width: 5%">

        </td>
        <td valign="top" style="padding-left: 0.0px; width: 88%; text-align: left">
          <p style="margin-bottom: 0px; margin-top: 0px">
            News Release &#8211; <b>Aurinia Resolves Temporary Non-Compliance
            with Nasdaq&#8217;s Audit Committee Composition Rule</b>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>

    </p>
    <p>
      Exhibit 99.1 included with this report on Form 6-K is hereby
      incorporated by reference as an exhibit to the Registrant&#8217;s Registration
      Statement on Form F-10 (File No. 333-206994), as amended or supplemented.
    </p>
    <p>
      <br>

    </p>
    <p>

    </p>
    <p>

    </p>
    <p style="text-align: center">
      3
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a51588345_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2017 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman; font-size: 12pt"><b>Aurinia
      Resolves Temporary Non-Compliance with Nasdaq&#8217;s Audit Committee
      Composition Rule</b></font>
    </p>
    <p>
      VICTORIA, British Columbia--(BUSINESS WIRE)--July 12, 2017--Aurinia
      Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (&#8220;Aurinia&#8221; or the
      &#8220;Company&#8221;) today announced the receipt of a letter from The NASDAQ Stock
      Market LLC, regarding the Company&#8217;s recent temporary failure to comply
      with the Nasdaq&#8217;s audit committee composition requirement under Rule
      5605(c)(2)(A), which requires among other things, that each member of a
      company&#8217;s audit committee meet the criteria for independence set forth
      Rule 10A-3(b)(1) under the U.S. Securities Exchange Act of 1934, as
      amended. On May 8, 2017, the Board of Directors mistakenly appointed the
      Company&#8217;s Chief Executive Officer, Dr. Richard Glickman, to the audit
      committee in response to the resignation of a Board member from the
      Board of Directors. Pursuant to Canadian securities laws, there is an
      exemption from the independence requirements for the composition of a
      company&#8217;s audit committee in response to a resignation of one of the
      members of the audit committee. However, as Dr. Glickman is an executive
      officer he does not meet the criteria for independence set forth in Rule
      10A-3(b)(1), and is not eligible to sit on the audit committee under
      NASDAQ rules. As a result, for a period of 44 days the Company was not
      in compliance with NASDAQ Rule 5605(c)(2)(A).
    </p>
    <p>
      On June 21, 2017, following the Company&#8217;s Annual General Meeting of
      Shareholders and prior to being contacted by The NASDAQ Stock Market
      LLC, the Board of Directors reconstituted the audit committee, so that
      Dr. Glickman was no longer a member of the audit committee and therefore
      the Company regained compliance with NASDAQ Rule 5605(c)(2)(A). The
      Company has been advised by The NASDAQ Stock Market LLC, that it
      considers this matter closed.
    </p>
    <p>
      <i><b>About Aurinia</b></i><br>Aurinia is a clinical stage
      biopharmaceutical company focused on developing and commercializing
      therapies to treat targeted patient populations that are suffering from
      serious diseases with a high unmet medical need. The company is
      currently developing voclosporin, an investigational drug, for the
      treatment of LN. The company is headquartered in Victoria, BC and
      focuses its development efforts globally. <u>www.auriniapharma.com</u>
    </p>
    <p>

    </p>
    <p>
      CONTACT:<br><b>Investor Contact:</b><br>Aurinia Pharmaceuticals Inc.<br>Celia
      Economides<br>Vice President, Public Affairs<br><u>ceconomides@auriniapharma.com</u>
    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
